Viruses Diagnostic Assay Panel

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: CMV Antibody IgG, IgM, CMV IgG, IgM Abs, Cytomegalovirus Antibodies IgG IgM

Cytomegalovirus

Cytomegalovirus

Also known as: EBV, EBV Panel , Epstein Barr Virus (EBV) Panel, EpsteinBarr Virus EBV Antibody Panel

Ebv Nuclear Ag (Ebna)

Epstein-Barr virus (EBV) is a virus that typically causes a mild to moderate illness. These tests detect antibodies to EBV in the blood and help establish a diagnosis of an EBV infection. Epstein-Barr virus causes an infection that is very common. According to the Centers for Disease Control and Prevention (CDC), as many as 95% of people in the United States will have been infected by EBV by the time they are 40 years old.

Ebv Viral Capsid Ag (Vca)

Epstein-Barr virus (EBV) is a virus that typically causes a mild to moderate illness. These tests detect antibodies to EBV in the blood and help establish a diagnosis of an EBV infection. Epstein-Barr virus causes an infection that is very common. According to the Centers for Disease Control and Prevention (CDC), as many as 95% of people in the United States will have been infected by EBV by the time they are 40 years old.

Ebv Viral Capsid Ag (Vca)

Epstein-Barr virus (EBV) is a virus that typically causes a mild to moderate illness. These tests detect antibodies to EBV in the blood and help establish a diagnosis of an EBV infection. Epstein-Barr virus causes an infection that is very common. According to the Centers for Disease Control and Prevention (CDC), as many as 95% of people in the United States will have been infected by EBV by the time they are 40 years old.

Also known as: Ebv Early Antigen D Ab IgG

Ebv Early Antigen D

SARS COV 2 AB (IGG)

*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through Quest Diagnostics. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 Quest Diagnostics laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The Viruses Diagnostic Assay Panel panel contains 4 tests with 7 biomarkers.

Name: Viruses Diagnostic Assay Panel

Tests Included:

  • Cytomegalovirus Antibodies (IgG, IgM)
  • Epstein-Barr Virus (EBV) Antibody Panel
  • Epstein-Barr Virus Early Antigen D Antibody (IgG)
  • SARS COV 2 AB (IGG) SPIKE, SEMI QN

Description:

The Viruses Diagnostic Assay Panel is a comprehensive set of tests specifically designed to identify and quantify antibodies produced in response to viral infections. By measuring the presence of these antibodies, the panel provides valuable insights into both current and past exposures to specific viruses, aiding in diagnosis, treatment planning, and monitoring of viral infections.

  • Cytomegalovirus Antibodies (IgG, IgM): These antibodies indicate exposure or infection with Cytomegalovirus (CMV). The presence of IgM antibodies suggests a recent or active infection, while IgG antibodies indicate past exposure or a later stage of infection.

  • Epstein-Barr Virus (EBV) Antibody Panel: This is a set of tests that detect antibodies to different components of the EBV, helping to diagnose and differentiate between active, past, or reactivated EBV infections.

  • Epstein-Barr Virus Early Antigen D Antibody (IgG): Indicates an active or recent reactivation of an EBV infection. Elevated levels of this antibody can be found in individuals experiencing symptomatic EBV or in those with complications associated with the virus.

  • SARS COV 2 AB (IGG) SPIKE, SEMI QN: This test identifies and quantifies the IgG antibodies against the spike protein of the SARS-CoV-2 virus, the causative agent of COVID-19. A semi-quantitative result provides an approximate concentration of antibodies, aiding in understanding the immune response post-infection or post-vaccination.

Purpose:

The Viruses Diagnostic Assay Panel serves various critical functions, such as:

1. Offering a Clear Diagnosis of Viral Infections by Identifying Specific Antibodies:

The cornerstone of effective medical intervention lies in accurate diagnosis. The Viruses Diagnostic Assay Panel provides clinicians with the tools to pinpoint specific viral infections by detecting antibodies associated with them. When the body encounters a virus, it produces unique antibodies in response, each tailored to combat that specific invader. By identifying these antibodies in a patient's blood, the panel offers definitive evidence of exposure to a particular virus, allowing for a more precise diagnosis. This specificity minimizes the guesswork and ensures patients receive the most appropriate care tailored to their needs.

2. Helping Healthcare Providers Differentiate Between Active, Past, or Reactivated Viral Infections:

Viruses can interact with the human body in various ways. Some may cause immediate symptoms, while others can lie dormant and reactivate after a period. Furthermore, after an infection has passed, antibodies can remain in the system for an extended time. The Viruses Diagnostic Assay Panel can discern between these scenarios by identifying and quantifying different types of antibodies (e.g., IgM typically indicates recent exposure, whereas IgG suggests past infection). Such differentiation is essential because a reactivated virus or a current infection may require different clinical approaches than a past infection.

3. Guiding Treatment and Management Decisions Based on the Type and Stage of Infection:

Understanding the stage and type of a viral infection is crucial in determining the appropriate treatment regimen. Early-stage infections may benefit from antiviral medications to reduce severity, while late-stage or reactivated infections might require symptom management or supportive care. Moreover, knowing the exact viral culprit can influence the selection of antiviral agents, as some drugs are more effective against specific viruses. The panel provides a roadmap for healthcare providers, allowing them to navigate the complex landscape of therapeutic options to optimize patient outcomes.

4. Providing Insights into the Immune System's Response to Infections or Vaccinations:

Immune response is a critical indicator of how the body is defending itself against viral invaders or reacting to a vaccine. By tracking specific antibodies, the Viruses Diagnostic Assay Panel offers a window into this complex defensive mechanism. Elevated levels of antibodies can indicate a robust immune response, while low levels might suggest a compromised immune system or a need for booster vaccinations. In the era of vaccines and therapeutic advancements, understanding an individual's immune response can guide vaccination strategies, assess vaccine efficacy, and provide peace of mind to patients and healthcare providers alike.

In essence, the Viruses Diagnostic Assay Panel acts as a multifaceted tool, granting insights into the nuanced interactions between viruses and the human body. Its precise, comprehensive data informs healthcare strategies, ensuring each patient receives personalized, evidence-based care.

 

Customer Reviews